Insomnia drug market will exceed $5.6 billion in 2013

Aug 16 2004

Decision Resources forecasts that the insomnia drug market will exceed $5.6 billion in 2013. The new Pharmacor study entitled Insomnia finds that upcoming launches of three new drugs from Sepracor, Pfizer, and Sanofi-Aventis will drive the market.

"Growth in the U.S. market, which represents more than 75% of the seven- country insomnia market, will drive overall growth of the worldwide market because of the relatively high price of drugs in this country and the comparatively aggressive marketing of prescription drugs directly to patients in the United States," said Tricia Nagle, analyst at Decision Resources. "Insomniacs are an ideal target for direct-to-consumer advertising because so many individuals suffer from the condition but fail to discuss it with their primary care providers."

Ms. Nagle continued: "Overall growth of elderly populations in the seven major pharmaceutical markets we cover (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will also expand the potential market for insomnia therapies in the next ten years because insomnia is especially prevalent among elderly individuals. This segment of the insomnia population remains highly untapped."